These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35118420)

  • 1. Platelet Membrane-Coated Nanocarriers Targeting Plaques to Deliver Anti-CD47 Antibody for Atherosclerotic Therapy.
    Chen L; Zhou Z; Hu C; Maitz MF; Yang L; Luo R; Wang Y
    Research (Wash D C); 2022; 2022():9845459. PubMed ID: 35118420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.
    Kojima Y; Volkmer JP; McKenna K; Civelek M; Lusis AJ; Miller CL; Direnzo D; Nanda V; Ye J; Connolly AJ; Schadt EE; Quertermous T; Betancur P; Maegdefessel L; Matic LP; Hedin U; Weissman IL; Leeper NJ
    Nature; 2016 Aug; 536(7614):86-90. PubMed ID: 27437576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE
    Song Y; Huang Z; Liu X; Pang Z; Chen J; Yang H; Zhang N; Cao Z; Liu M; Cao J; Li C; Yang X; Gong H; Qian J; Ge J
    Nanomedicine; 2019 Jan; 15(1):13-24. PubMed ID: 30171903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sonodynamic Therapy Promotes Efferocytosis via CD47 Down-Regulation in Advanced Atherosclerotic Plaque.
    Cao Y; Yao J; Gao W; Cao Z; Diabakte K; Wang L; Sun X; Tian Y
    Int Heart J; 2022 Jan; 63(1):131-140. PubMed ID: 35034916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and characterization of atherosclerotic target anti-CD47 functionalized by nano-polyelectrolyte complexes between chitosan and hyaluronic acid and in vivo and in vitro targeting experiments.
    Yu J; Ruan Q; Nie X
    Adv Clin Exp Med; 2020 Dec; 29(12):1407-1415. PubMed ID: 33389831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation.
    Ye ZM; Yang S; Xia YP; Hu RT; Chen S; Li BW; Chen SL; Luo XY; Mao L; Li Y; Jin H; Qin C; Hu B
    Cell Death Dis; 2019 Feb; 10(2):138. PubMed ID: 30755588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nano-bioconjugate modified with anti-SIRPα antibodies and antisense oligonucleotides of mTOR for anti-atherosclerosis therapy.
    Liu Y; Huang Q; He M; Chen T; Chu X
    Acta Biomater; 2024 Mar; 176():356-366. PubMed ID: 38160854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis.
    Jarr KU; Kojima Y; Weissman IL; Leeper NJ
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e145-e154. PubMed ID: 35387480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice.
    Thorp E; Cui D; Schrijvers DM; Kuriakose G; Tabas I
    Arterioscler Thromb Vasc Biol; 2008 Aug; 28(8):1421-8. PubMed ID: 18451332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy.
    Patel Y; Manturthi S; Tiwari S; Gahunia E; Courtemanche A; Gandelman M; Côté M; Gadde S
    ACS Pharmacol Transl Sci; 2024 Oct; 7(10):3086-3095. PubMed ID: 39416959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD47- and Integrin α4/β1-Comodified-Macrophage-Membrane-Coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque.
    Li Y; Che J; Chang L; Guo M; Bao X; Mu D; Sun X; Zhang X; Lu W; Xie J
    Adv Healthc Mater; 2022 Feb; 11(4):e2101788. PubMed ID: 34786845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting and clearance of senescent foamy macrophages and senescent endothelial cells by antibody-functionalized mesoporous silica nanoparticles for alleviating aorta atherosclerosis.
    Pham LM; Kim EC; Ou W; Phung CD; Nguyen TT; Pham TT; Poudel K; Gautam M; Nguyen HT; Jeong JH; Yong CS; Park SY; Kim JR; Kim JO
    Biomaterials; 2021 Feb; 269():120677. PubMed ID: 33503557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unleashing the biomimetic targeting potential of platelet-derived nanocarriers on atherosclerosis.
    Jan N; Bostanudin MF; Moutraji SA; Kremesh S; Kamal Z; Hanif MF
    Colloids Surf B Biointerfaces; 2024 Aug; 240():113979. PubMed ID: 38823339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of myeloid cell-specific SIRPα, but not CD47, attenuates inflammation and suppresses atherosclerosis.
    Singla B; Lin HP; Ahn W; Xu J; Ma Q; Sghayyer M; Dong K; Cherian-Shaw M; Zhou J; Huo Y; White J; Csányi G
    Cardiovasc Res; 2022 Dec; 118(15):3097-3111. PubMed ID: 34940829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques.
    Egaña-Gorroño L; Chinnasamy P; Casimiro I; Almonte VM; Parikh D; Oliveira-Paula GH; Jayakumar S; Law C; Riascos-Bernal DF; Sibinga NES
    Atherosclerosis; 2019 Oct; 289():184-194. PubMed ID: 31439353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular and extracellular synergistic therapy for restoring macrophage functions via anti-CD47 antibody-conjugated bifunctional nanoparticles in atherosclerosis.
    Luo Q; Dai L; Li J; Chen H; Hao Y; Li Q; Pan L; Song C; Qian Z; Chen M
    Bioact Mater; 2024 Apr; 34():326-337. PubMed ID: 38274294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms.
    Tajbakhsh A; Rezaee M; Kovanen PT; Sahebkar A
    Pharmacol Ther; 2018 Aug; 188():12-25. PubMed ID: 29444453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice.
    Sastre C; Fernández-Laso V; Madrigal-Matute J; Muñoz-García B; Moreno JA; Pastor-Vargas C; Llamas-Granda P; Burkly LC; Egido J; Martín-Ventura JL; Blanco-Colio LM
    J Cell Mol Med; 2014 Apr; 18(4):721-34. PubMed ID: 24479820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect.
    Sha X; Dai Y; Chong L; Wei M; Xing M; Zhang C; Li J
    J Nanobiotechnology; 2022 Dec; 20(1):506. PubMed ID: 36456996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolvin D1 promotes the targeting and clearance of necroptotic cells.
    Gerlach BD; Marinello M; Heinz J; Rymut N; Sansbury BE; Riley CO; Sadhu S; Hosseini Z; Kojima Y; Tang DD; Leeper NJ; Spite M; Barroso M; Rayner KJ; Fredman G
    Cell Death Differ; 2020 Feb; 27(2):525-539. PubMed ID: 31222041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.